Literature DB >> 15538986

Illness of Immune Reconstitution: Recognition and Management.

Edward M Gardner1, Elizabeth Connick.   

Abstract

Some individuals who initiate highly active antiretroviral therapy (HAART) develop new or worsening opportunistic infections or malignancies despite improvements in surrogate markers of HIV-1 infection. These events of paradoxical clinical worsening, also known as immune reconstitution syndromes (IRS), are increased in individuals with prior opportunistic infections or low CD4+ T-cell nadirs. They are thought to result from reconstitution of the immune system's ability to recognize pathogens or tumor antigens that were previously present, but clinically asymptomatic. There is no consensus regarding the diagnostic criteria or pathogenesis of IRS. Knowledge of their presentation and treatment is largely based on case reports. With the introduction of HAART into resource-limited settings, it is likely that significantly more and distinct forms of IRS will be observed. Prospective studies of the incidence and treatment of IRS in multiple settings are critical to better understand their pathogenesis and optimal management.

Entities:  

Year:  2004        PMID: 15538986     DOI: 10.1007/s11908-004-0068-4

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  138 in total

1.  Mediastinal lymphadenitis due to cryptococcal infection in HIV-positive patients on highly active antiretroviral therapy.

Authors:  M Lanzafame; M Trevenzoli; G Carretta; L Lazzarini; S Vento; E Concia
Journal:  Chest       Date:  1999-09       Impact factor: 9.410

2.  Reactivation of hepatitis B in patients with human immunodeficiency virus infection treated with combination antiretroviral therapy.

Authors:  L A Proia; S L Ngui; S Kaur; H A Kessler; G M Trenholme
Journal:  Am J Med       Date:  2000-02-15       Impact factor: 4.965

Review 3.  Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy.

Authors:  W J Burman; B E Jones
Journal:  Am J Respir Crit Care Med       Date:  2001-07-01       Impact factor: 21.405

4.  Case report. Recurrence of increased intracranial pressure with antiretroviral therapy in an AIDS patient with cryptococcal meningitis.

Authors:  S K Cinti; W S Armstrong; C A Kauffman
Journal:  Mycoses       Date:  2001-12       Impact factor: 4.377

5.  Effect of highly active antiretroviral therapy on frequency of oral warts.

Authors:  D Greenspan; A J Canchola; L A MacPhail; B Cheikh; J S Greenspan
Journal:  Lancet       Date:  2001-05-05       Impact factor: 79.321

6.  Pyomyositis and cutaneous abscesses due to Mycobacterium avium: an immune reconstitution manifestation in a patient with AIDS.

Authors:  Stephen D Lawn; Tihana A Bicanic; Derek C Macallan
Journal:  Clin Infect Dis       Date:  2004-02-01       Impact factor: 9.079

7.  Herpes zoster infection in HIV-seropositive patients associated with highly active antiretroviral therapy.

Authors:  T Aldeen; P Hay; F Davidson; R Lau
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

8.  The changing face of AIDS-related opportunism: cryptococcosis in the highly active antiretroviral therapy (HAART) era. Case reports and literature review.

Authors:  R Manfredi; F Pieri; S A Pileri; F Chiodo
Journal:  Mycopathologia       Date:  1999-11       Impact factor: 2.574

9.  Varicella zoster as a manifestation of immune restoration disease in HIV-infected children.

Authors:  Nutthapong Tangsinmankong; Wasu Kamchaisatian; Jorge Lujan-Zilbermann; Cynthia L Brown; John W Sleasman; Patricia J Emmanuel
Journal:  J Allergy Clin Immunol       Date:  2004-04       Impact factor: 10.793

10.  Paradoxical reactions in HIV and pulmonary TB.

Authors:  J W Chien; J L Johnson
Journal:  Chest       Date:  1998-09       Impact factor: 9.410

View more
  1 in total

1.  Prevalence and intensity of Schistosoma mansoni infection in pediatric populations on antiretroviral therapy in north-western Tanzania: a cross-sectional study.

Authors:  Humphrey D Mazigo; Laurence Kirway; Emmanuela Ausebio Ambrose
Journal:  BMJ Open       Date:  2019-07-24       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.